Response to letter - Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists

Eur J Cancer. 2017 Dec:87:204. doi: 10.1016/j.ejca.2017.06.042. Epub 2017 Jul 26.

Author

Lucie-Marie Scailteux¹

Affiliation

¹ Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Rennes Hospital University, France; UPRES, EA 7449, REPERES "Research in Pharmacoepidemiology and Access to Care", Rennes, France. Electronic address: mary.obrien@rmh.nhs.uk.

PMID: 28756060
DOI: 10.1016/j.ejca.2017.06.042

No abstract available

Publication types

Letter
Comment

MeSH terms

Androgen Antagonists*
Cardiovascular Diseases*
Gonadotropin-Releasing Hormone / antagonists & inhibitors
Hormone Antagonists
Humans
Prostatic Neoplasms
Risk Factors

Substances

Androgen Antagonists
Hormone Antagonists
Gonadotropin-Releasing Hormone